ACE and COVID-19: Importantly, our in vitro findings that ACE inhibition and angiotensin blockade does not appear to affect SARS-CoV-2 infectivity or increase cell death further support the American Heart Association’s recommendations to continue RAS inhibitors in COVID-19 patients however larger clinical studies are needed to assess this effect in clinical populations.